English | 简体中文 | 繁體中文 | 한국어 | 日本語
 Press Releases for Tuesday, March 14, 2023
Prenetics公布2022年第四季度及全年财务业绩 新业务策略专注于精准肿瘤学 
22:07 HKT/SGT
Prenetics公布2022年第四季度及全年財務業績 新業務策略專注於精準腫瘤學 
22:06 HKT/SGT
Prenetics Announces Fourth Quarter and Full Year 2022 Financial Results, New Business Strategy Focused on Precision Oncology 
22:05 HKT/SGT
NFT-TiX Secures VIP Lounge Naming Rights for Hardmission and Techmission Festival Prague 2023 
21:01 HKT/SGT
富通保险推出限时震撼优惠 预缴全期保费可享保证5%年利率 
16:32 HKT/SGT
富通保險推出限時震撼優惠 預繳全期保費可享保證5%年利率 
16:31 HKT/SGT
日立・京都大学・リバーセルが、他家T細胞療法の普及に向け、自動培養技術開発のための共同研究契約を締結 
16:00 HKT/SGT
Think Equity: Society Pass (Nasdaq: SOPA) - Path to Profitability 
14:00 HKT/SGT
中国通海金融委任旗下中国通海资产管理行政总裁 
12:32 HKT/SGT
中國通海金融委任旗下中國通海資產管理行政總裁 
12:31 HKT/SGT
Tonghai Financial Announces Appointment of Christopher Tang to CEO of China Tonghai Asset Management 
12:30 HKT/SGT
中国通海金融宣布委任旗下中国通海企业融资(控股)联席主席 
12:29 HKT/SGT
中國通海金融宣布委任旗下中國通海企業融資(控股)聯席主席 
12:28 HKT/SGT
Tonghai Financial Announces Appointment of Ambrose Lam as Co-Chairman of China Tonghai Capital (Holdings) Limited 
12:27 HKT/SGT
亞洲聯合基建簽訂11億港元三年期之定期貸款協議 
11:22 HKT/SGT
Asia Allied Infrastructure Concludes HK$1.1 Billion 3-Year Term Loan Agreement 
11:21 HKT/SGT
U.S. Veterans' Health Administration (VHA) Provides Coverage of LEQEMBI (lecanemab-Irmb) Two Months After LEQEMBI's FDA Accelerated Approval for Veterans Living with Early Stages of Alzheimer's Disease 
10:09 HKT/SGT
ソニー、「2023 World's Most Ethical Companies(世界で最も倫理的な企業)」の1社に選定 
09:30 HKT/SGT
エーザイ、早期アルツハイマー病治療薬「LEQEMBI(TM)」(レカネマブ)について、米国退役軍人保健局が FDA による迅速承認から 2 カ月で保険適用を開始 
09:30 HKT/SGT
ADEC Innovations 收購 Kedge Pty Ltd 和 Southern Ocean Carbon Company 
06:21 HKT/SGT
ADEC Innovations 收购 Kedge Pty Ltd 和 Southern Ocean Carbon Company 
06:21 HKT/SGT
ADEC Innovations Acquires Kedge Pty Ltd and Southern Ocean Carbon Company 
06:21 HKT/SGT
 ACN Search:
 
Paw Pro GmbH Announces $1.5M Partnership with Health Reasoning to Launch Innovative Web3 Platform
 
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575